Allogene Therapeutics Inc (NYSE:ALLO) Q2 2020 Earnings Conference Call - Final Transcript
Aug 05, 2020 • 08:30 am ET
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Allogene Therapeutics Second Quarter 2020 Conference Call. [Operator Instructions]
I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and good morning. Before market opened today, Allogene issued a press release that provides a corporate update and financial results for the second quarter ended June 30, 2020. This press release is available on our website at www.allogene.com. We remind listeners that today's call is being webcast on our website and will be available for replay.
Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer. We continue to conduct calls from different locations. So we appreciate your patience should we have any technical difficulties.
During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities and 2020 financial guidance, among other things.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change. These statements may involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended June 30, 2020. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.
I'll now turn the call over to Dr. David Chang.
Thank you, Christine. Good morning, and thank you for joining us on our second quarter conference call. The last few months have been very exciting for Allogene as we unveil the first clinical data from our AlloCAR T portfolio at ASCO. We were very pleased with the initial data from the ongoing ALPHA trial with ALLO-501 and what it means for our allogeneic platform as it paves the way for the development of ALLO-501A, which we expect to enter into a potential pivotal Phase II trial in 2021.
Key findings from our initial Phase I data presentation include that ALLO-501 with ALLO-647 as a part of the lymphodepletion regimen was well tolerated with no dose-limiting toxicities, graft-versus-host disease or Immune Effector Cell-Associated Neurotoxicity Syndrome in heavily pretreated patients with advanced non-Hodgkin's lymphoma. We continue to believe that our anti-CD52 antibody, ALLO-647, will be one of the important components in our ability to achieve the promise of AlloCAR T therapies.
Initial data from the ALPHA trial supports our strategy with a higher dose of ALLO-647 being associated with a higher complete response rate. Of the eight patients who received a higher dose of ALLO-647 of 90-milligram, five or 63% had a partial response and four